[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Future University in Egypt\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":474},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,42,82,105,139,166,191,213,236,260,283,303,323,348,368,394,415,438,453],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100644130","influence-of-acetal-resin-versus-nylon-elastic-cap-on-crestal-bone-loss-in-mandibular-implant-supported-overdenture-100644130",false,"NCT07666763","Influence of Acetal Resin Versus Nylon Elastic Cap on Crestal Bone Loss in Mandibular Implant-Supported Overdenture","AcetalResin","Inclusion Criteria:\n\n* Completely edentulous mandible.\n* Sufficient bone height\u002Fwidth in mandibular residual ridges.\n* Angles classification class I.\n* Sufficient inter-arch distance\n\nExclusion Criteria:\n\n* TMJ disorders.\n* Diabetic\n* Hypertensive\n* Cancer patients.\n* Smoker\n* Osteoporosis.\n* Immunosuppressive disease\n* Any disease affecting bone\u002Fimplant stability.",true,"MALE","40 Years","60 Years",{"count":21,"type":22},22,"ESTIMATED","INTERVENTIONAL",[25],"NA","Objective: To evaluate and compare the effect of two different attachment housing materials-Acetal Resin (Polyoxymethylene) versus conventional Nylon elastic caps-on marginal crestal bone loss around dental implants supporting a mandibular overdenture. It also evaluates peri-implant clinical tissue health by measuring pocket depth and the gingival bleeding index.",[28,29],"Bone Loss","Pocket, Periodontal","NOT_YET_RECRUITING","2026-06-21",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":22},"2026-07-01",{"date":38,"type":22},"2027-08-01",{"name":40,"class":41},"Future University in Egypt","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100637934","assessment-of-soft-tissue-thickness-over-zygomatic-implants-in-atrophied-maxilla-covered-with-buccal-fat-pad-vs-palatal-pedicle-flap-100637934","NCT07574606","Assessment of Soft Tissue Thickness Over Zygomatic Implants in Atrophied Maxilla Covered With Buccal Fat Pad vs. Palatal Pedicle Flap","Inclusion Criteria:\n\nPatients ≥18 years with severely atrophic maxilla.\n\n* Acquired maxillary defects resulting from trauma, pathology, or previous surgical resection.\n* Indicated for zygomatic implant-supported fixed prosthesis.\n* Sufficient mouth opening for zygomatic implants placement.\n* Patients willing to sign informed consent and attend follow-ups.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease affecting healing (e.g., uncontrolled diabetes, etc).\n* Heavy smokers\n* Previous radiotherapy or bisphosphonate therapy.\n* Active sinus or nasal infection.\n* Severe parafunctional habits (e.g., bruxism).\n* Pregnant or lactating women.\n* Patients with psychiatric disorders affecting compliance.","ALL","18 Years",{"count":51,"type":22},4,[25],"Background and Rationale The rehabilitation of the severely atrophied maxilla utilizing zygomatic implants is a highly predictable and effective treatment modality. However, managing the peri-implant soft tissue in these complex cases remains a significant clinical challenge. Because zygomatic implants frequently emerge through thin, non-keratinized, and mobile alveolar mucosa rather than thick, attached gingiva, the peri-implant environment is highly susceptible to complications. Inadequate soft tissue thickness can lead to mucosal recession, exposure of the implant collar, plaque accumulation, and ultimately peri-implantitis, which threatens the long-term success of the prosthesis.\n\nTo mitigate these risks and achieve an optimal permucosal seal, soft tissue augmentation is often required. Vascularized soft tissue grafts are preferred in these compromised anatomical sites due to their robust blood supply and enhanced healing capacity. The Buccal Fat Pad (BFP) flap is a well-documented and frequently utilized technique for this purpose; however, its volume can be unpredictable, and it may be unavailable due to prior surgeries or anatomical deficiencies. Therefore, evaluating robust alternatives, such as the Palatal Pedicle Flap (PPF)-which utilizes the thick, keratinized palatal mucosa-is critical for optimizing surgical outcomes.\n\nStudy Design and Methodology This study is structured as a prospective, randomized controlled clinical trial utilizing a split-mouth design. The split-mouth approach is strategically chosen to eliminate inter-subject biological and immunological variability, allowing each patient to effectively serve as their own control. Patients presenting with a severely resorbed maxilla requiring bilateral zygomatic implant placement will be enrolled.\n\nFollowing successful implant placement, the right and left maxillary quadrants will be randomized. One side will be assigned to receive soft tissue augmentation using the standard Buccal Fat Pad (BFP) flap, while the contralateral side will be assigned to receive the Palatal Pedicle Flap (PPF).\n\nSurgical Intervention Overview All surgical procedures will be performed under appropriate anesthesia following standard sterile protocols.\n\nFor the BFP side: The buccal fat pad will be accessed via a vestibular mucosal incision, carefully bluntly dissected, mobilized, and advanced over the zygomatic implant collar without tension.\n\nFor the PPF side: A palatal pedicle flap will be meticulously outlined, elevated with its vascular supply intact, rotated, and adapted around the contralateral implant collar.\n\nBoth flaps will be secured using appropriate resorbable sutures to ensure tension-free primary closure and optimal tissue adaptation around the implant abutment interface. Post-operative care will adhere to standard institutional guidelines, including the prescription of appropriate analgesics, antibiotics, and antimicrobial mouth rinses.\n\nClinical Significance By systematically comparing the healing trajectories, tissue stability, and functional outcomes of the BFP and PPF techniques over a 6-month period, this trial aims to provide definitive, evidence-based guidance for soft tissue management in zygomatic implantology. Furthermore, it seeks to validate the PPF as a reliable and predictable reconstructive alternative in clinical scenarios where the buccal fat pad is deemed insufficient or inaccessible.",[55,56,57,58,59,60,61,62],"Atrophic Edentulous Maxilla","Zygomatic Implants","Dental Implant","Soft Tissue Augmentation at Dental Implants","Soft Tissue Coverage","Buccal Fat Pad","Palatal Pedicle Flap","Zygomatic Implant Recession",[64,65,66,67,68,69,70,71],"atophic edentulous maxilla","zygomatic implants","dental implants","soft tissue augmentation at dental implant site","soft tissue coverage","buccal fat pad","palatal pedicle flap","zygomatic implant recession","RECRUITING","2026-05-18",{"date":75,"type":34},"2026-05-20",{"date":77,"type":34},"2025-11-03",{"date":79,"type":22},"2026-08",{"name":40,"class":41},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":48,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100639436","remineralization-potential-of-bioactive-varnish-100639436","NCT07602660","Remineralization Potential of Bioactive Varnish","Remineralization Potential of Bioactive Varnish Versus Sodium Fluoride Varnish in Management of White Spot Lesions: Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients within 16-35 years of age.\n2. Each patient has 4 or more WSLs\n3. Mild and moderate WSLs.\n4. Good oral hygiene and willing patients who can attend study visits.\n5. Symmetrical number of permanent teeth in each arch (mesial to second molars).\n\nExclusion Criteria:\n\n1. Active carious lesions.\n2. Labial surface restorations.\n3. Intrinsic and extrinsic stains.\n4. Patients who have a significant medical history or if they are smokers.\n5. Patients who participated in clinical study during the preceding six months of the start of this trial.\n6. Criteria for discontinuation; Mortality and acquiring severe debilitating disease.","16 Years","35 Years",{"count":92,"type":22},60,[25],"This randomized controlled trial is held to investigate the effectiveness of two remineralizing agents surface pre-reacted glass-ionomer (S-PRG) filler and fluoride in management of white spot lesions.",[96],"White Spot Lesion","2026-05-16",{"date":99,"type":34},"2026-05-22",{"date":101,"type":22},"2026-06",{"date":103,"type":22},"2026-12",{"name":40,"class":41},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":16,"sex":48,"minAge":49,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100637854","postoperative-pain-and-substance-p-levels-after-bioceramic-vs-calcium-hydroxide-intracanal-medicaments-in-symptomatic-apical-periodontitis-100637854","NCT07585721","Postoperative Pain and Substance P Levels After Bioceramic vs Calcium Hydroxide Intracanal Medicaments in Symptomatic Apical Periodontitis","Clinical Evaluation of the Postoperative Pain and Substance P Levels Following the Use of Bioceramic Verses Calcium Hydroxide Intracanal Medicaments in Permanent Mandibular Molars With Symptomatic Apical Periodontitis","(BCvsCaOH)","Inclusion Criteria:\n\n* \\- Patients aged 18-45 years with no sex predilection\n* Medically free Patients with no systemic conditions that can affect post operative pain response.\n* Patients should not be taking any pain medications 24 hours before intervention\n* Positive patients' acceptance for participating in the study\n* Patient able to sign informed consent\n* Permanent mandibular molars diagnosis with Symptomatic Apical Periodontitis\n* Permanent molars without any anatomical variations or severe curvatures\n\nExclusion Criteria:\n\n* \\- Medically compromised patients\n* Patients who have received antibiotic therapy within the last 2 weeks.\n* Pregnant or lactating women.\n* Patients with known allergy to any of the irrigants used.\n* Patients with swelling or acute peri-apical abscess or fistulous tract.\n* Teeth that have:\n* Wide or open apex .\n* Vital pulp tissue .\n* Periodontally affected with grade 2or 3 mobility.\n* Non restorable teeth .\n* Abnormal anatomy and calcified canals .\n* Pervious root canal treatment.\n* severe curved canal\n* Buccolingual and mesiodistal radiographs were taken to evaluate the root canal anatomy","45 Years",{"count":115,"type":22},28,[25],"Clinical Evaluation of the Postoperative Pain and Substance P levels Following the use of Bioceramic verses Calcium Hydroxide Intracanal Medicaments in Permanent Mandibular molars with Symptomatic Apical Periodontitis",[119],"Symptomatic Apical Periodontitis",[121,122,123,124,125,126,127,128,129,130,119],"Postoperative Pain","Substance P","Calcium Hydroxide","Bioceramic intra-canal medication","BIO-C TEMP","Mandibular Molars","Intra canal medication","Endodontics","Root Canal Treatment","inflammatory mediators","2026-05-10",{"date":133,"type":34},"2026-05-14",{"date":135,"type":22},"2026-06-01",{"date":137,"type":22},"2027-02-01",{"name":40,"class":41},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":165,"locationsCount":81},"100635310","evaluation-of-zygomatic-implant-placement-accuracy-using-fully-metallic-vs-resin-based-static-surgical-guides-in-severely-atrophic-maxilla-100635310","NCT07551024","Evaluation of Zygomatic Implant Placement Accuracy Using Fully Metallic vs Resin-based Static Surgical Guides in Severely Atrophic Maxilla","Evaluation of Zygomatic Implant Placement Accuracy Using Fully Metallic vs Resin-based Surgical Guides in Severely Atrophic Maxilla.","guided surgery","Inclusion Criteria:\n\n* Patients ≥18 years with severely atrophic maxilla.\n* Acquired maxillary defects resulting from trauma, pathology, or previous surgical resection.\n* Indicated for zygomatic implant-supported fixed prosthesis.\n* Sufficient mouth opening for zygomatic implants placement.\n* Patients willing to sign informed consent and attend follow-ups.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease affecting healing (e.g., uncontrolled diabetes, etc).\n* Heavy smokers\n* Previous radiotherapy or bisphosphonate therapy.\n* Active sinus or nasal infection.\n* Severe parafunctional habits (e.g., bruxism).\n* Pregnant or lactating women.\n* Patients with psychiatric disorders affecting compliance.",{"count":51,"type":22},[25],"Some patients lose a large amount of bone in the upper jaw. When this happens, it can be difficult to place regular dental implants. In these cases, special implants called zygomatic implants can be used. These implants are longer than normal implants and are fixed in the cheekbone, which usually has enough bone to support them. They can help support fixed teeth for patients with severe bone loss in the upper jaw.\n\nPlacing zygomatic implants requires careful planning and high accuracy. To help guide the surgeon during the operation, a surgical guide can be used. A surgical guide is a custom-made device that helps the surgeon place the implant in the planned position.\n\nSurgical guides can be made from different materials. The most common type is made from resin (a strong plastic material) using 3D printing. Recently, fully metallic surgical guides have been developed. These metal guides may be stronger and more stable during surgery, but it is not yet clear if they improve the accuracy of implant placement.\n\nThe purpose of this study is to compare the accuracy of metal surgical guides and resin surgical guides when placing zygomatic implants in patients with severe bone loss in the upper jaw.\n\nPatients included in the study will undergo a clinical examination and a CT scan before surgery to plan the implant positions. During the surgery, each patient will receive zygomatic implants on both sides of the upper jaw. On one side, the implants will be placed using a metal surgical guide, and on the other side, they will be placed using a resin surgical guide. This allows the two types of guides to be compared in the same patient.\n\nAfter the surgery, another CT scan will be taken to check the final position of the implants. The planned implant position will be compared with the actual position after surgery to measure the accuracy of placement.\n\nThe results of this study will help determine whether metallic surgical guides or resin surgical guides provide better accuracy when placing zygomatic implants.\n\nParticipation in this study is voluntary. All patients will receive full information about the study and will sign a consent form before participating.",[55,56,151,57,152],"Guided Surgery","Accuracy of Dental Implant Placement",[154,155,156,157,158,159],"Zygomatic implants","Severely atrophic maxilla","Surgical guides","Dental implant placement accuracy","Metal surgical guide","Resin surgical guide","2026-05-04",{"date":162,"type":34},"2026-05-07",{"date":77,"type":34},{"date":101,"type":22},{"name":40,"class":41},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":81},"100619692","effect-of-pre-hospital-arni-therapy-on-short-term-outcomes-in-hfref-100619692","NCT07347925","Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF","Evaluating the Impact of Pre-Hospital Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy on Short-Term Clinical Outcomes in Heart Failure Patients With Reduced Ejection Fraction: A Comparative Study","Inclusion Criteria:\n\n* \\>= 18 years, male or female EF \\\u003C40%\n\nExclusion Criteria:\n\n* EF\\>40% Pregnancy or breastfeeding",{"count":174,"type":22},140,"OBSERVATIONAL","This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.\n\nThe study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital.\n\nSome participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.",[178],"Heart Failure",[178,180,181,182],"NYHA class","Sacubitril\u002FValsartan","Chronic kidney disease","2026-01-11",{"date":185,"type":34},"2026-01-16",{"date":187,"type":22},"2026-01-10",{"date":189,"type":22},"2026-05-01",{"name":40,"class":41},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":16,"sex":48,"minAge":49,"maxAge":18,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":81},"100565288","the-effect-of-xp-endo-finisher-activation-of-bioceramic-sealer-on-postoperative-pain-in-mandibular-first-molar-with-symptomatic-irreversible-pulpitis-100565288","NCT06640231","The Effect of XP-Endo Finisher Activation of Bioceramic Sealer on Postoperative Pain in Mandibular First Molar With Symptomatic Irreversible Pulpitis","Inclusion Criteria:\n\n* Age ranges from 18 to 40 years old.\n* No sex predilection.\n* Patients seeking root canal treatment.\n* Systematically healthy patient (ASA I, II).\n* Patient who can understand numerical rate scale and sign an informed consent.\n* Mandibular first molar teeth with:\n\n  * Preoperative sharp (moderate or severe) pain.\n  * Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).\n  * Normal periapical radiographic appearance.\n\nExclusion Criteria:\n\n* Patients with American association of anesthesiologists (ASA) classification other than ASA T\\& II.\n* Patients who have already ingested preoperative medication, such as analgesics, non-steroidal or steroidal anti-inflammatory drugs, within 12 hours of the start of treatment.\n* Patients with NSAIDs allergy.\n* Patients having two or more adjacent teeth needing root canal therapy.\n* Pregnant patients.\n* Patients with bleeding disorder.\n* Patients with long term corticosteroid use\n* Teeth having;\n\n  * Necrotic pulp.\n  * History or presence of swelling or fistulous tract.\n  * Acute \u002F chronic periapical abscess.\n  * Mobility more than grade 1.\n  * Pocket depth more than 5mm.\n  * No possible restorability.\n  * Previous root canal treatment.\n  * Periapical radiolucency.\n  * External or internal resorption.\n  * Vertical root fracture.\n* TMJ problems, bruxism, clenching or traumatic occlusion.\n* Inability to understand and perform the given instructions.",{"count":198,"type":22},30,[25],"The aim of endodontic obturation is to make a complete sealing along the length of the root canal system to ensuring the peri radicular tissue healing and sustained health. Disadvantages of gutta-percha-based root filling materials is lack of adhesiveness to canal wall dentin. So, a sealer or cement has to be used with gutta-percha to achieve a fluid-tight seal and fill the space between the canal wall dentin and the obturating material.\n\nDrawbacks of resin-based sealer are difficult preparation technique of deep root canal cavity which also limit dentin bonding, difficult to be removed from the canal in retreatment cases and its shrinkage during setting.\n\nBio-ceramic root canal sealers become popular in recent years because of their unique chemical and physical properties. These sealers are consisting of biocompatible materials that resemble the of tooth structure natural composition so bio-ceramic sealers are an ideal choice for root canal treatment. Bio-ceramic sealers are better than traditional sealers due to their multiple physical properties for example excellent sealing ability, dimensional stability, and low solubility. These properties ensure that the sealers achieve a tight seal, inhibiting bacterial leakage and decreasing the risk of reinfection. Diaroot Bioaggregate (DiaDent), a white nanoparticle-sized ceramic cement composed of calcium silicate, calcium hydroxide and hydroxyapatite and considered a modified version of MTA, with the advantage of being aluminium-free in composition, a fact that contributes to its greater biocompatibility with periradicular tissue.Root canal sealers activation may improve their penetration into dentinal tubules and improve sealability and antimicrobial effects.\n\nRecently, a non-tapered nickel-titanium rotary instrument (XP-endo Finisher; FKG, La Chaux-de-Fonds, Switzerland) has been designed to increase the efficiency in root canal wall cleaning specifically with limited impact on dentine throughout the literature, XP efficacy in decreasing microorganisms, dissolving organic tissue from artificial cavities in combination with NaOCl and penetrating into the isthmus has been analyzed.\n\nThe aim of this study to evaluate the effect of XP-Endo Finisher activation of Bioceramic sealer on postoperative pain in mandibular first molar with symptomatic irreversible pulpitis.\n\nThis study consists of 30 patients divided into 2 group each group having 15 patients.\n\nIntervention:\n\nBioceramic sealer activation with XP Endo Finisher.\n\nControl group:\n\nBioceramic sealer without activation.",[202],"Symptomatic Irreversible Pulpitis",[204],"Postoperative pain","2025-06-25",{"date":207,"type":34},"2025-06-29",{"date":209,"type":34},"2024-11-01",{"date":211,"type":22},"2026-04-01",{"name":40,"class":41},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":16,"sex":48,"minAge":219,"maxAge":19,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100589157","aesthetic-performance-of-two-injectable-resin-composites-in-class-v-cavities-a-randomized-clinical-trial-100589157","NCT06950762","Aesthetic Performance of Two Injectable Resin Composites in Class V Cavities: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 20-60 years.\n2. Co-operative participants approving to participate in the study.\n3. Male or female patients.\n4. Medically free participants.\n5. Moderate or high caries risk participants.\n\nExclusion Criteria:\n\n1. Systemic disease or severe medical complications.\n2. Participants with a history of allergy to any component of restorations will be used in the study.\n3. Lack of compliance\n4. Evidence of severe bruxism, clenching, or temporomandibular joint disorders or bizarre habits","20 Years",{"count":221,"type":22},50,[25],"Using bioactive injectable resin composite in anterior class v carious lesions can provide better aesthetic outcome and marginal integrity by releasing multiple ions, including fluoride. This offers better marginal integrity due to presence of S-PRG fillers",[225],"Restoration of Carious Class v Anterior Teeth",[227],"Giomer based injectable composite","2025-06-15",{"date":230,"type":34},"2025-06-18",{"date":232,"type":22},"2025-06-10",{"date":234,"type":22},"2026-04-13",{"name":40,"class":41},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":16,"sex":48,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100584809","comparison-of-the-functional-properties-of-two-injectable-materials-in-posterior-teeth-randomized-clinical-trial-100584809","NCT06894186","Comparison of the Functional Properties of Two Injectable Materials in Posterior Teeth: Randomized Clinical Trial","Inclusion Criteria:\n\n* 1-Adult patients (20-50) 2-Good oral hygiene Good oral hygiene (Plaque index ≤2 (Moderate accumulation with plaque in the sulcus)) 3-Patient approval 4-Absence of parafunctional habits and\u002For bruxism 5-No endodontic treatment or abscess 6- class II either mesial or distal (no MOD cavities)\n\nExclusion Criteria:\n\n* 1\\. Systematic disease that may affect participation. 2. Xerostomic patients. 3. Bad oral hygiene (plaque index 2 or 3) 14 4. Heavy smokers 5. Patients undergoing or will start orthodontic treatment 6. Signs and symptoms of irreversible pulpitis.","21 Years","50 Years",{"count":245,"type":22},52,[25],"Using two different injectable materials in class II cavities to compare functional properties",[249,250,251],"Class II Dental Caries","Dental Caries","Injectable Composite","2025-03-24",{"date":254,"type":34},"2025-03-25",{"date":256,"type":22},"2025-03",{"date":258,"type":22},"2026-04",{"name":40,"class":41},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":16,"sex":48,"minAge":219,"maxAge":243,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100585323","the-effect-of-bulk-filling-flowable-composite-on-caries-recurrence-in-deep-marginal-elevation-a-randomized-clinical-trial-100585323","NCT06900868","The Effect of Bulk Filling Flowable Composite on Caries Recurrence in Deep Marginal Elevation: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults patients (20-50)\n* Good oral hygiene (plaque index 0 or 1 )\n* Patient approving to participate in the study\n* Absence of parafunctional habits and\u002For bruxism\n* No sign of irreversible pulpitis\n* No periapical radiolucency\n* Deep subgingival margin\n* Molars class II with subgingival margin\n\nExclusion Criteria:\n\n* • Patients with known allergic or adverse reaction to the tested materials.\n\n  * Systematic disease that may affect participation.\n  * Xerostomic patients.\n  * Bad oral hygiene (plaque index 2 or 3 )\n  * Heavy smokers\n  * Patients undergoing or will start orthodontic treatment\n  * Patients with removable prothesis",{"count":221,"type":22},[25],"Deep marginal elevation usinge a bioactive dental material in deep subgingival Class II restorations, S-PRG filler-containing materials offer significant benefits due to their bioactive properties, Their ability to release fluoride, remineralization potential and acid neutralization, reducing the risk of recurrent caries, particularly at the gingival margin(Imazato et al. 2023). The antibacterial and antifungal effects help inhibit biofilm formation, enhancing the longevity of restorations. Additionally, these materials support better marginal adaptation by reducing microleakage and improving bond durability (Imazato et al. 2023) This type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health(Imazato et al. 2023).",[270,250,271,272],"DME","Dental","Deep Margin Elevation",[274],"Deep margin elevation","2025-03-22",{"date":277,"type":34},"2025-03-28",{"date":279,"type":22},"2025-03-20",{"date":281,"type":22},"2026-04-20",{"name":40,"class":41},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":48,"minAge":219,"maxAge":243,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":4},"100583900","performance-of-bioactive-low-viscosity-composite-in-deep-marginal-elevation-restorations-100583900","NCT06882343","Performance of Bioactive Low Viscosity Composite in Deep Marginal Elevation Restorations","Performance of Bioactive Low Viscosity Composite in Deep Marginal Elevation Restorations: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults patients (20-50)\n* Good oral hygiene (plaque index 0 or 1 )\n* Patient approving to participate in the study\n* Absence of parafunctional habits and\u002For bruxism\n\nExclusion Criteria:\n\n* Patients with known allergic or adverse reaction to the tested materials.\n* Systematic disease that may affect participation.\n* Xerostomic patients.\n* Bad oral hygiene (plaque index 2 or 3 )\n* Heavy smokers\n* Patients undergoing or will start orthodontic treatment\n* Patients with removable prothesis",{"count":221,"type":22},[25],"The goal of this study is to evaluate the clinical, radiographic and periodontal performance of bioactive Giomer Shofu Flow Plus X F03 compared to nanohybrid resin composite restoration in deep subgingival proximal cavities over a period of 12 months.",[294,295],"Deep Caries","Caries, Dental","2025-03-18",{"date":298,"type":34},"2025-03-21",{"date":300,"type":22},"2025-04-01",{"date":211,"type":22},{"name":40,"class":41},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":16,"sex":48,"minAge":219,"maxAge":18,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100577902","evaluation-of-postoperative-pain-and-antimicrobial-efficacy-of-selenium-versus-calcium-hydroxide-as-intracanal-medication-in-mandibular-first-molars-with-necrotic-pulp-and-symptomatic-apical-periodontitis-100577902","NCT06804330","Evaluation of Postoperative Pain and Antimicrobial Efficacy of Selenium Versus Calcium Hydroxide As Intracanal Medication in Mandibular First Molars with Necrotic Pulp and Symptomatic Apical Periodontitis","Inclusion Criteria:\n\n* Medically free patients with no systemic disease: (American Society of Anesthesiologists \u002F (ASA Class I or II).\n\n  * Age range is between 20 to 40 years.\n  * No sex predilection.\n  * Patients having necrotic pulp with symptomatic apical periodontitis in mandibular first molars.(type l distal root canal ) .\n  * Sensitive to percussion.\n  * Periapical radiographic appearance of teeth showed slight widening in lamina dura.\n  * restorable teeth.\n  * Positive patient\"s acceptance for participating in the study.\n  * Patients able to sign informed consent.\n\nExclusion Criteria:\n\n* Medically compromised patients.\n\n  * Pregnant or lactating females.\n  * Psychologically disturbed patients.\n  * Patients with a history of allergy to any medication used in the study were excluded.\n  * If anti-inflammatory analgesics or antibiotics have been administrated by patient during the past 12 hours preoperatively.\n  * Patients with swelling or acute peri-apical abscess or fistulous tract.\n\nTeeth that have:\n\n* Wide or open apex.\n* Vital pulp tissues.\n* Periodontally affected with grade 2 or 3 mobility.\n* Not restorable teeth.\n* Abnormal anatomy and calcified canals.\n* Previous root canal treatment.",{"count":92,"type":22},[25],"The main rational behind intracanal medicament is to kill the bacteria inside the root canal and to avert reinfection. In absence of nutrients, the bacteria remains after obturation in root canal may not survive. Otherwise they may flourish \\& If the root canal is not dressed properly with antiseptic medicaments between the visits, the residual bacteria may increase . Thus the use of effective intracanal medication for disinfection of root canal is necessitated . Medicament with long effect and least irritated to periradicular tissue has to be introduced to infiltrate the dentinal tubule eliminating bacteria . As the effect of intracanal medicaments is longer than irrigants, it is generally recommended to fill the root canal between appointments with intracanal medicaments. Calcium hydroxide is the most commonly recommended antimicrobial agent for interappointment medications. It serves as an effective intracanal medicament due to its alkaline pH, which inhibits bacterial growth. However, calcium hydroxide has limitations. .Recently selenium(Se) was introduced as intracanal medication .Se is a mineral essential for the formation of the amino acid selenocysteine, which is directly involved in the maintenance of the immune response. Selenium has been widely used in the medical field in the treatment of cancer, as an activator of bone metabolism, and as a stimulator of the immune system. In this study, it will show that the incorporation of Se, whether as intracanal medication alone or in conjunction with other medications, may potentiate periapical tissue repair after RCS cleaning and shaping procedures.\n\nThis study consists of 60 patients divided into 3 group each group having 20 patient.\n\nIntervention 1: intracanal medication using selenium alone .\n\nIntervention 2: intracanal medication using selenium with calcium hydroxide",[313,314,315],"Necrotic Pulp with Symptomatic Apical Periodontitis","Postoperative Dental Pain","Antimicrobial Effect","2025-03-17",{"date":318,"type":34},"2025-03-19",{"date":300,"type":22},{"date":321,"type":22},"2025-10-01",{"name":40,"class":41},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":81},"100578831","phase-3-impact-of-varying-doses-of-prucalopride-on-improving-gut-function-recovery-after-elective-colorectal-surgery-100578831","NCT06816407","Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery","The Effect of Different Doses of Prucalopride on Improving Gut Function Recovery Following Elective Colorectal Surgery: a Randomized, Double-blind Study","Inclusion Criteria:\n\n* undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Total colectomy\n* Creation of a stoma\n* Pre-existing gastrointestinal disorders\n* Severe renal or hepatic impairment\n* Known hypersensitivity to prucalopride.","75 Years",{"count":332,"type":22},180,[334],"PHASE3","Postoperative ileus (POI) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. Management remains challenging, with limited pharmacological options available. Prucalopride, a selective serotonin 5-HT4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. However, the optimal timing and dosing for preventing POI remains unclear. Higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.",[337],"Post-Op Complication",[339,340],"pro kinetic","gut function recovery","2025-03-15",{"date":318,"type":34},{"date":344,"type":34},"2025-03-02",{"date":346,"type":22},"2025-05",{"name":40,"class":41},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":16,"sex":48,"minAge":219,"maxAge":243,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":367,"locationsCount":4},"100583378","clinical-performance-of-high-viscosity-bioactive-injectable-composite-in-deep-marginal-elevation-100583378","NCT06875544","Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation","Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation Randomized Controlled Trail","Randomized","Inclusion Criteria:\n\n1. Adult Patient (20-50 years old)\n2. Good oral hygiene (plaque index 0 or 1)\n3. Patient approval\n4. Absence of parafunctional habits and\u002For bruxism\n5. No endodontic treatment\n6. No abscess\n7. No partial or fixed denture\n\nExclusion Criteria:\n\n1. Patients with known allergic or adverse reaction to the tested materials.\n2. Bad oral hygiene\n3. Systematic disease that may affect participation.\n4. Xerostomic patients.\n5. Patients with active periodontal disease.\n6. Heavy smokers (those who smoke greater than or equal to 25 or more cigarettes a day)\n7. Orthodontic treatment patient",{"count":221,"type":22},[25],"Using a bioactive resin composite in subgingival Class II cavities can provide enhanced caries resistance by releasing multiple ions, including fluoride. This approach offers greater resistance to caries due to the incorporation of surface pre-reacted glass filler (S-PRG) technology (Imazato, Nakatsuka et al., 2023).\n\nThis type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health.",[270,271,272],[361],"deep margin elevation","2025-03-08",{"date":364,"type":34},"2025-03-13",{"date":256,"type":22},{"date":258,"type":22},{"name":40,"class":41},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":374,"minAge":49,"maxAge":330,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":4},"100575638","phase-3-role-of-folic-acid-in-the-management-of-adjuvant-endocrine-therapy-induced-hot-flashes-in-breast-cancer-patients-100575638","NCT06774885","ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS","Inclusion Criteria:\n\n* Females older than 18 years\n* Diagnosed with confirmed breast cancer and currently treated with an adjuvant endocrine\n* Experiencing bothersome hot flashes at least 14 times\u002Fweek\n* Taking the treatment within 6 months to two years.\n\nExclusion Criteria:\n\n* Known hypersensitivity to folic acid\n* Patients who have been treated with selective serotonin reuptake inhibitors (SSRIs) within the past 30 days.\n* Renal impairment is defined as a serum creatinine level greater than 2 mg\u002Fld..\n* Significant liver disease: Indicated by liver enzyme levels exceeding two times the upper limit of normal.\n* Metastatic breast cancer\n* Taking other medication for hot flashes\n* Medications inducing hot flashes such as (Clomiphene, Opioids, Nifedipine, Prednisone)","FEMALE",{"count":376,"type":22},120,[334],"The study's objective is to investigate the role of folic acid administration in the management of hot flashes associated with adjuvant endocrine therapy in patients with breast cancer.",[380],"THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS",[382,383,384,385],"Breast cancer","Hot flashes","Endocrine therapy","Folic acid","2025-01-09",{"date":388,"type":34},"2025-01-14",{"date":390,"type":22},"2025-02-09",{"date":392,"type":22},"2025-08",{"name":40,"class":41},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":374,"minAge":49,"maxAge":18,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":81},"100560379","phase-3-efficacy-of-dapagliflozin-versus-metformin-in-polycystic-ovary-syndrome-100560379","NCT06576375","Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome: A Prospective Comparative Randomized Blinded Trial.","Inclusion Criteria:\n\n* Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.\n* Age: \\>18 \\\u003C40 years.\n* Infertile women (primary or secondary infertility)\n\nExclusion Criteria:\n\n* Patients with history of diabetes mellitus (Type 1 or 2).\n* Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months and uncontrolled endocrine or metabolic disease.\n* Use of hormonal medications, lipid-lowering (statins, etc.), anti-obesity drugs or weight loss medications (prescription or OTC) and medications known to exacerbate glucose tolerance (such as isotretinoin, hormonal contraceptives, glucocorticoids, anabolic steroids) stopped for at least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha reductase inhibitors stopped for at least 4 weeks.\n* Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.\n* Presence of hypersensitivity to dapagliflozin or other Sodium\u002Fglucose cotransporter 2 (SGLT2) inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions).\n* Use of Metformin, Thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders.\n* Having a history of bariatric surgery.",{"count":402,"type":22},70,[334],"In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight\u002Fobese individuals.\n\nConflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by preserving β-cell function in patients with impaired fasting glucose(IFG and impaired glucose tolerance(IGT). The study aims to compare the efficacy of Dapagliflozin to Metformin for the treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).",[406],"Polycystic Ovary Syndrome","2024-10-18",{"date":409,"type":34},"2024-10-22",{"date":411,"type":34},"2024-09-02",{"date":413,"type":22},"2025-01",{"name":40,"class":41},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":16,"sex":48,"minAge":422,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":81},"100565286","assessment-of-i-prf-versus-nano-mta-combined-with-i-prf-scaffold-in-vital-pulp-therapy-in-mature-mandibular-first-molars-100565286","NCT06640205","Assessment of I-PRF Versus Nano MTA Combined with I-PRF Scaffold in Vital Pulp Therapy in Mature Mandibular First Molars","Clinical and Radiographic Assessment of I-PRF Versus Nano Mineral Trioxide Aggregate Combined with I-PRF Scaffold in Vital Pulp Therapy in Mandibular First Molars with Closed Apices: \"Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Patients suffering from Symptomatic irreversible pulpitis in mature mandibular molars only will be involved.\n\n  * Patients of either gender aged from 15-30.\n  * Tooth should give positive response to cold test.\n  * The tooth is restorable\n  * Patients should be free from any systemic disease that may affect normal healing and predictable outcome.\n  * Patients who will agree to the consent and will commit to follow-up period.\n  * Patients with mature root.\n  * Patients with no internal or external resorption and no periapical lesions.\n  * Soft tissues around the tooth are normal with no swelling or sinus tract.\n\nExclusion Criteria:\n\n* Patients with immature roots.\n\n  * Haemostasias after 10 minutes can not be controlled after total pulpotomy\n  * Patients with periapical lesions or infections.\n  * Pregnant females.\n  * Patients with fistula or swelling\n  * Patients with necrotic pulp.","15 Years","30 Years",{"count":425,"type":22},51,[25],"Assessment of I-PRF versus Nano Mineral trioxide aggregate Combined with I-PRF in pulpotomy in mature Mandibular First Molars",[429],"Pulpotomy","2024-10-10",{"date":432,"type":34},"2024-10-15",{"date":434,"type":34},"2023-09-03",{"date":436,"type":22},"2025-09-02",{"name":40,"class":41},{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":48,"minAge":49,"maxAge":18,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":452,"locationsCount":81},"100565287","the-effect-of-eddy-sonic-versus-af-max-activation-of-bio-ceramic-sealer-on-post-operative-pain-in-teeth-with-symptomatic-irreversible-pulpitis-with-apical-periodontitis-100565287","NCT06640218","The Effect of Eddy Sonic Versus AF Max Activation of Bio-ceramic Sealer on Post-operative Pain in Teeth with Symptomatic Irreversible Pulpitis with Apical Periodontitis","Inclusion Criteria:\n\n* Age range is from 18 to 40 years old.\n* No sex predilection\n* Patients seeking root canal treatment.\n* restorable teeth.\n* Positive patient acceptance for participating in the study.\n* patients able to sign informed consent.\n* Systematically healthy patient (ASA I, Il).\n* Patient who can understand the numerical rate scale and sign an informed consent.\n* Mandibular first molar teeth with pain on bite or percussion\n* Preoperative sharp (moderate or severe) pain.\n* Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).\n* widening in periodontal membrane space in radiographic appearance.\n\nExclusion Criteria:\n\n* Patients with American Association of Anesthesiologists (ASA) classifications other than ASA 1 \\& Il\n* Patients who have already ingested preoperative medication, such as analgesics, non-steroidal, or steroidal anti-inflammatory drugs, within 12 hours of the start of treatment.\n* This was done to prevent any misinterpretation of the diagnosis or post-treatment pain severity, as these drugs substantially lower post-endodontic pain (Jorge-Arajo et al.,2018).\n* Patients with NSAID allergy.\n* Patients having two or more adjacent teeth needing root canal therapy\n* Pregnant patients.\n* Patients with bleeding disorder.\n* Patients with long-term corticosteroid use.\n* Teeth having:\n\n  * Necrotic pulp.\n  * History or presence of swelling or fistulous tract.\n  * Acute\u002Fchronic periapical abscess.\n  * Mobility more than grade 1.\n  * Pocket depth of more than 5mm\n  * No possible restorability.\n  * Previous root canal treatment.\n  * Periapical radiolucency.\n  * External or internal resorption\n  * Vertical root fracture.\n* TMJ problems, bruxism, clenching or traumatic occlusion.\n* Inability to understand and perform the given instructions.",{"count":198,"type":22},[25],"The aim of endodontic therapy for an inflamed tooth is to eliminate the source of inflammation. Relieving pain depends on the effectiveness of root canal therapy.3\n\nPostoperative pain in endodontic treatments, affecting 3-58% of patients, is often caused by peri-radicular tissue injuries. Understanding these factors helps professionals select methods and supplies to minimize discomfort.\n\n30 patients will be divided into 3 groups according to the method of activation (10 par ticipants\u002Feach). participants will be recruited from the postgrad clinic of the endodontic department faculty of oral and dental medicine, Future University in Egypt Patients with mature mandibular first permanent molar with irreversible pulpitis with apical periodontitis Intervention 1: bio-ceramic sealer activation with Eddy sonic Intervention 2: bio-ceramic sealer activation with AF max Control\u002FComparator: bio-ceramic sealer without activation The study aims to evaluate the effect of Eddy Sonic and AF max activation of bio-ceramic sealer on postoperative pain in mandibular first molars with symptomatic irreversible pulpitis with apical periodontitis",[448],"Irreversible Pulpitis with Apical Periodontitis",{"date":432,"type":34},{"date":209,"type":22},{"date":211,"type":22},{"name":40,"class":41},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":16,"sex":48,"minAge":422,"maxAge":423,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":81},"100563266","assessment-of-l-prf-nanohydroxyapatite-combined-with-l-prf-using-pulpotomy-in-mature-mandibular-first-molars-100563266","NCT06613932","Assessment of L-PRF, Nanohydroxyapatite Combined With L-PRF Using Pulpotomy in Mature Mandibular First Molars","Clinical and Radiographic Assessment of L-PRF, Nanohydroxyapatite Material Combined With L-PRF Scaffold in Vital Pulp Therapy. Treatments in Mandibular First Molars With Closed Apices \"Randomized Controlled Trial\"","Inclusion criteria:\n\nPatients should be free from any systemic disease. Patients of either gender aged from 15-30. Patients will agree to the consent and will commit to a follow-up period. Soft tissues around the tooth are normal with no swelling or sinus tract. The tooth is restorable tooth has signs and symptoms of irreversible pulpitis of the mature root The tooth doesn\\'t contain any internal or external resorption or periapical lesions.\n\nThe tooth should give a positive response to the cold test.\n\nExclusion criteria:\n\nPregnant and lactating females. Patients with Mental disturbance. Patients who could\u002Fwould not participate in a 6-month follow-up. A tooth with immature roots. Patients with necrotic pulp.• tooth with periapical lesions or infections. Soft tissue having fistula or swelling Homoeostasis after 10 minutes can not be controlled after total pulpotomy",{"count":461,"type":22},45,[25],"Clinical and Radiographic Assessment of L-PRF, Nanohydroxyapatite material combined with L-PRF scaffold in Vital pulp Therapy. Treatments in Mandibular First Molars with Closed Apices, Randomized Controlled Trial.",[465],"Irreversible Pulpitis","2024-09-25",{"date":468,"type":34},"2024-09-26",{"date":470,"type":34},"2023-10-30",{"date":472,"type":22},"2024-10-30",{"name":40,"class":41},""]